Bicara Therapeutics earnings were N/A for the trailing 12 months ending Mar 31, 2025, with N/A growth year over year. The latest BCAX earnings report on Mar 31, 2025 announced Q1 2025 earnings of -$36.8M, up 75.8% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, BCAX reported annual earnings of -$68.0M, with 30.8% growth.
BCAX earnings history
Current Revenue
$0.0
Current Earnings
$0.0
Current Profit Margin
0%
BCAX Return on Equity
Insufficient data to display
BCAX undefined
Insufficient data to display
Be the first to know when BCAX announces earnings.
Bicara Therapeutics Earnings Reports & History FAQ
What were Bicara Therapeutics's earnings last quarter?
Bicara Therapeutics (NASDAQ: BCAX) reported Q1 2025 earnings per share (EPS) of -$0.68, up 96.41% year over year. Total BCAX earnings for the quarter were -$36.85 million. In the same quarter last year, Bicara Therapeutics's earnings per share (EPS) was -$18.94.
Is Bicara Therapeutics profitable or losing money?
As of the last Bicara Therapeutics earnings report, Bicara Therapeutics is currently losing money. Bicara Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2025 was N/A, a N/A decrease year over year.
What was BCAX's earnings growth in the past year?
As of Bicara Therapeutics's earnings date in Q2 2025, Bicara Therapeutics's earnings has grown year over year. BCAX earnings in the past year totalled N/A.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.